Melanie Lee, formerly president of new medicines and executive vice president for R&D at UCB, has been appointed chief executive officer of Syntaxin Ltd, a UK biotechnology company which is developing cell secretion inhibitors for endocrine, inflammatory and neurological disorders. Dr Lee was director of R&D at Celltech before that company was acquired by UCB of Belgium.
Copyright 2010 Evernow Publishing Ltd